Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection
Publication Type:
Journal Article
Authors:
Bourliere, Marc;
Gordon, Stuart C.;
Flamm, Steven L.;
Cooper, Curtis L.;
Ramji, Alnoor;
Tong, Myron;
Ravendhran, Natarajan;
Vierling, John M.;
Tran, Tram T.;
Pianko, Stephen;
Bansal, Meena B.;
de Lédinghen, Victor;
Hyland, Robert H.;
Stamm, Luisa M.;
Dvory-Sobol, Hadas;
Svarovskaia, Evguenia;
Zhang, Jie;
Huang, K. C.;
Subramanian, G. Mani;
Brainard, Diana M.;
McHutchison, John G.;
Verna, Elizabeth C.;
Buggisch, Peter;
Landis, Charles S.;
Younes, Ziad H.;
Curry, Michael P.;
Strasser, Simone I.;
Schiff, Eugene R.;
Reddy, K. Rajender;
Manns, Michael P.;
Kowdley, Kris V.;
Zeuzem, Stefan;
POLARIS-1 and POLARIS-4 InvestigatorsSource:
N Engl J Med, Volume 376, Issue 22, p.2134-2146 (2017)
Keywords:
Adult,
Aged,
Aged, 80 and over,
Antiviral Agents,
Carbamates,
Drug Combinations,
Drug Resistance, Viral,
Female,
Genotype,
Hepacivirus,
Hepatitis C,
Heterocyclic Compounds, 4 or More Rings,
Humans,
Liver Cirrhosis,
Macrocyclic Compounds,
Male,
Middle Aged,
Protease Inhibitors,
sofosbuvir,
Sulfonamides,
Viral Nonstructural Proteins
